Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Tirumotecan + Tislelizumab in Advanced ESCC
NCT07811752Phase 2Recruiting
- Sponsor
- Shanghai Chest Hospital
- Start
- Jul 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab tirumotecan in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Shanghai Chest Hospital. Started Jul 2026; status: recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07811752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07811752.